A Phase II trial to study the impact of BPM31510 on platelet and skeletal muscle mitochondrial energetics in healthy adults
Latest Information Update: 15 Mar 2023
At a glance
- Drugs Ubidecarenone (Primary)
- Indications Epidermolysis bullosa; Glioblastoma; Glioma; Pancreatic cancer; Squamous cell cancer
- Focus Pharmacodynamics
- 08 Feb 2023 According to a BPG Bio media release, Berg Pharma has been acquired by BPG Bio.
- 22 Dec 2020 New trial record
- 15 Dec 2020 According to a Berg media release, the company announced a research collaboration with AdventHealth to conduct investigations employing BERG's Interrogative Biology platform, so as to examine potential biomarker signatures of age-related disease. The collaboration will include investigation of effect of BPM 31510 on platelet and skeletal muscle mitochondrial energetics in a phase II study in healthy adults.